NCT02726711View on ClinicalTrials.gov

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Multiple System AtrophyOrthostatic HypotensionSupine Hypertension
Interventions
DRUG

Trimethaphan

Trimethaphan will be infused (0.5 - 4.0 mg IV)

DRUG

Placebo

0.5 - 4.0 mg IV to be infused

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER